Related Experiment Video
Updated: Dec 29, 2025

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
Published on: May 21, 2019
MicroRNA‑628‑5p inhibits cell proliferation and induces apoptosis in colorectal cancer through downregulating CCND1
1Department of General Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei 075061, P.R. China.
Abstract:
MicroRNA (miR)‑628‑5p serves as an antitumor gene in a variety of cancers; however, the role of miR‑628‑5p in colorectal cancer remains largely unclear. The purpose of this study was to investigate the role and mechanism of miR‑628‑5p in colorectal cancer. Reverse transcription‑quantitative PCR (RT‑qPCR), colony formation assays and flow cytometric analysis were used to determine the expression levels of miR‑628‑5p in colorectal cancer tissues and cell lines, and the proliferative ability of colorectal cancer cells. TargetScan version 7.2 and dual‑luciferase reporter assay were performed to predict and confirm miR‑628‑5p target genes. The expression levels of cyclin D1 (CCND1) and related genes were determined using RT‑qPCR or/and western blotting analysis. miR‑628‑5p mimics and CCND1 plasmids were used to overexpress miR‑628‑5p and CCND1; it was demonstrated that the expression levels of miR‑628‑5p were significantly downregulated in colorectal cancer tissues and cell lines. miR‑628‑5p mimic‑transfected cells inhibited the proliferation and induced apoptosis of HT‑29 cells. CCND1, a downstream effector of miR‑628‑5p, promoted the proliferation and suppressed apoptosis of HT‑29 cells, and the effects were reversed by miR‑628‑5p mimics. In conclusion, the present study suggested that colorectal cancer progression may be regulated through the miR‑628‑5p/CCND1 axis, and miR‑628‑5p could be used as a potential diagnostic and prognostic biomarker for colorectal cancer.
Insights
MicroRNA-628-5p is downregulated in colorectal cancer, inhibiting proliferation and inducing apoptosis. Its axis with cyclin D1 (CCND1) suggests miR-628-5p as a potential biomarker for colorectal cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MicroRNA (miR)-628-5p exhibits antitumor properties in various cancers.
- The specific function of miR-628-5p in colorectal cancer (CRC) is not well-defined.
- Understanding miR-628-5p's role is crucial for developing novel CRC therapeutic strategies.
Purpose of the Study:
- To elucidate the role and underlying mechanism of miR-628-5p in colorectal cancer.
- To investigate miR-628-5p's impact on CRC cell proliferation and apoptosis.
- To identify potential therapeutic targets within the miR-628-5p pathway.
Main Methods:
- Quantitative PCR (RT-qPCR) and western blotting to assess gene expression.
- Colony formation assays and flow cytometry for proliferation and apoptosis analysis.
- Bioinformatic prediction (TargetScan) and dual-luciferase reporter assays to identify miR-628-5p targets.
Main Results:
- miR-628-5p expression was significantly downregulated in colorectal cancer tissues and cell lines.
- Overexpression of miR-628-5p inhibited proliferation and induced apoptosis in HT-29 cells.
- Cyclin D1 (CCND1) was identified as a direct target of miR-628-5p, promoting proliferation and suppressing apoptosis; these effects were reversed by miR-628-5p mimics.
Conclusions:
- Colorectal cancer progression is potentially regulated by the miR-628-5p/CCND1 axis.
- miR-628-5p demonstrates potential as a diagnostic and prognostic biomarker for colorectal cancer.
- Targeting the miR-628-5p/CCND1 pathway may offer a novel therapeutic approach for colorectal cancer.
Related Concept Videos
MicroRNAs
MicroRNAs
Abnormal Proliferation
Experimental RNAi
Inhibition of Cdk Activity

